Debt-to-equity of Cartesian Therapeutics, Inc. from 31 Mar 2017 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Cartesian Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 31 Mar 2017 to 30 Sep 2025.
  • Cartesian Therapeutics, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was -2498%, a 818% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Cartesian Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 -2498% -2226% -818% 30 Sep 2025
Q2 2025 -5660% -5429% -2350% 30 Jun 2025
Q1 2025 -1374% -1141% -489% 31 Mar 2025
Q4 2024 -797% -528% -196% 31 Dec 2024
Q3 2024 -272% -365% -393% 30 Sep 2024
Q2 2024 -231% -332% -330% 30 Jun 2024
Q1 2024 -233% -334% -332% 31 Mar 2024
Q4 2023 -269% -378% -347% 31 Dec 2023
Q3 2023 93% -73% -44% 30 Sep 2023
Q2 2023 101% -242% -71% 30 Jun 2023
Q1 2023 101% -980% -91% 31 Mar 2023
Q4 2022 109% +3630% 31 Dec 2022
Q3 2022 166% +1406% 30 Sep 2022
Q2 2022 343% +1874% 30 Jun 2022
Q1 2022 1081% +2212% 31 Mar 2022
Q4 2021 -3521% -2340% -198% 31 Dec 2021
Q3 2021 -1240% +998% +45% 30 Sep 2021
Q2 2021 -1531% +223% +13% 30 Jun 2021
Q1 2021 -1132% +4229% +79% 31 Mar 2021
Q4 2020 -1181% -2435% -194% 31 Dec 2020
Q3 2020 -2237% -6397% -154% 30 Sep 2020
Q2 2020 -1753% -2909% -252% 30 Jun 2020
Q1 2020 -5360% -5873% -1146% 31 Mar 2020
Q4 2019 1254% +938% +297% 31 Dec 2019
Q3 2019 4159% +3995% +2429% 30 Sep 2019
Q2 2019 1155% +1047% +971% 30 Jun 2019
Q1 2019 512% +435% +562% 31 Mar 2019
Q4 2018 316% +246% +350% 31 Dec 2018
Q3 2018 164% +102% +161% 30 Sep 2018
Q2 2018 108% +55% +105% 30 Jun 2018
Q1 2018 77% +30% +62% 31 Mar 2018
Q4 2017 70% 31 Dec 2017
Q3 2017 63% 30 Sep 2017
Q2 2017 53% 30 Jun 2017
Q1 2017 48% 31 Mar 2017
* An asterisk sign (*) next to the value indicates that the value is likely invalid.